ERBB2 and breast cancer: In an independent data set (METABRIC) (46), the intermediate EMP cell gene signature showed a BC subtype–dependent correlation with patient-related outcomes; while there was no correlation in luminal tumors, high expression of the intermediate EMP cell signature was associated with worse RFS in patients with basal or HER2-like BC (Figure 5D).